JNJ
Johnson & Johnson (NYSE: JNJ) announced results from the final analysis of the Phase 3 PROTEUS study...
Article Summary
HOLD- Johnson & Johnson (NYSE: JNJ) announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy given for six months before and after prostate cancer surgery significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease.
- The trial met both primary endpoints, with patients treated with APALUTAMIDS plus hormone treatment nine times more likely to have little to no cancer remaining at the time of surgery compared with hormone therapy alone (8.9 percent vs. 1.0 percent) The combination also reduced the risk of developing metastasis or death by 20 percent and extended the time before patients required subsequent therapy to more than six years.
- The findings will be presented in a plenary session at the 2026 American Society of Clinical Oncology Annual Meeting (Oral Abstract #LBA1) and published simultaneously in The New England Journal of Medicine.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 7.9% | 25% | 35.0 ptsBelow Screener (7.9%) - Weak growth |
| EPS Growth Next 5Y ? | 9.2% | 25% | 20.0 ptsWeak (9.2%) - Low expectations |
| Target Price Upside ? | 16.2% | 20% | 60.0 ptsModerate Upside (16.2%) - Target: $261.90 vs Current: $225.33 |
| Gross Margin % ? | 68.0% | 15% | 80.0 ptsVery Healthy (68.0%) - High-quality margins |
| Drawdown from 52-Wk High ? | -10.5% | 15% | 40.0 ptsMild Pullback (-10.5%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About JNJ
- Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
- It operates in two segments, Innovative Medicine and MedTech.
- The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
- The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
- This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand.
- The company was founded in 1886 and is based in New Brunswick, New Jersey.